Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$2.23 -36.5%	$3.03	$1.84 ▼ $5.31	$77.36M	1.63	239,791 shs	13.00 million shs
RIGL Rigel Pharmaceuticals	$19.48 +3.8%	$19.48	$7.48 ▼ $29.82	$348.11M	1.29	210,601 shs	551,164 shs
VNDA Vanda Pharmaceuticals	$4.78 -0.8%	$4.39	$3.81 ▼ $6.37	$281.69M	0.66	613,089 shs	716,308 shs
VSTM Verastem	$4.15 -0.2%	$6.61	$2.10 ▼ $9.10	$228.04M	0.85	1.23 million shs	5.15 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	0.00%	-33.43%	-36.10%	-16.48%	-52.55%
RIGL Rigel Pharmaceuticals	0.00%	+2.91%	+0.93%	+8.28%	+136.98%
VNDA Vanda Pharmaceuticals	0.00%	+5.99%	+8.88%	+4.14%	-15.40%
VSTM Verastem	0.00%	-15.82%	-44.30%	-31.18%	+39.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHV Achieve Life Sciences	1.5819 of 5 stars	3.8	0.0	0.0	2.4	0.0	0.6
RIGL Rigel Pharmaceuticals	2.8187 of 5 stars	3.2	0.0	0.0	1.6	1.7	3.1
VNDA Vanda Pharmaceuticals	4.5534 of 5 stars	3.8	2.0	4.2	2.0	3.3	1.3
VSTM Verastem	2.798 of 5 stars	3.5	3.0	0.0	1.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.50	Strong Buy	$14.33	542.75% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	86.86% Upside
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	245.19% Upside
VSTM Verastem	3.00	Buy	$13.38	222.29% Upside

Current Analyst Ratings Breakdown

Latest ACHV, RIGL, VSTM, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00
5/14/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$13.00
5/13/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/7/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
4/1/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.61 per share	N/A
RIGL Rigel Pharmaceuticals	$179.28M	1.94	$1.08 per share	18.06	$0.19 per share	102.53
VNDA Vanda Pharmaceuticals	$198.77M	1.42	N/A	N/A	$9.24 per share	0.52
VSTM Verastem	$10K	22,804.25	N/A	N/A	($0.65) per share	-6.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$39.83M	-$1.34	N/A	N/A	N/A	N/A	-176.11%	-103.32%	8/12/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$2.07	9.41	18.55	N/A	18.31%	-655.26%	24.47%	8/5/2025 (Estimated)
VNDA Vanda Pharmaceuticals	-$18.90M	-$0.75	N/A	N/A	N/A	-21.98%	-8.30%	-6.85%	7/30/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.20	N/A	N/A	N/A	N/A	-2,003.62%	-127.97%	8/6/2025 (Estimated)

Latest ACHV, RIGL, VSTM, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/7/2025	Q1 2025	VNDA Vanda Pharmaceuticals	-$0.55	-$0.50	+$0.05	-$0.50	$45.13 million	$50.04 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.85	3.51	3.51
RIGL Rigel Pharmaceuticals	2.42	2.20	2.13
VNDA Vanda Pharmaceuticals	N/A	3.93	3.91
VSTM Verastem	2.77	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
RIGL Rigel Pharmaceuticals	66.23%
VNDA Vanda Pharmaceuticals	88.14%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	3.00%
RIGL Rigel Pharmaceuticals	9.04%
VNDA Vanda Pharmaceuticals	8.90%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	34.69 million	33.64 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.26 million	Optionable
VNDA Vanda Pharmaceuticals	290	58.93 million	53.69 million	Optionable
VSTM Verastem	50	54.95 million	53.80 million	Optionable

ACHV, RIGL, VSTM, and VNDA Headlines

Recent News About These Companies

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Brokerages

June 28 at 2:35 AM | marketbeat.com

Cantor Fitzgerald Reduces Earnings Estimates for Verastem

June 28 at 2:35 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) Stock Rating Upgraded by Royal Bank Of Canada

June 27 at 2:19 AM | americanbankingnews.com

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

June 26, 2025 | seekingalpha.com

FY2025 EPS Estimates for Verastem Cut by Cantor Fitzgerald

June 26, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - Morningstar

June 26, 2025 | morningstar.comM

Royal Bank Of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock Price

June 25, 2025 | marketbeat.com

Insider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)

June 24, 2025 | gurufocus.com

Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 Shares

June 24, 2025 | marketbeat.com

Dan Paterson Sells 17,808 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock

June 24, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

June 24, 2025 | businesswire.com

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges

June 15, 2025 | investing.com

Verastem reports promising cancer drug trial results

June 3, 2025 | investing.com

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

June 3, 2025 | businesswire.com

Verastem’s Promising Clinical Advances and Strategic Developments Justify Buy Rating

June 3, 2025 | tipranks.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from Brokerages

June 3, 2025 | marketbeat.com

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

June 2, 2025 | msn.com

Verastem Announces Strategic Plans in Investor Webcast

June 2, 2025 | tipranks.com

What's Going On With Verastem Oncology Stock On Monday?

June 2, 2025 | benzinga.com

Verastem, Inc. (NASDAQ:VSTM) Short Interest Update

June 2, 2025 | marketbeat.com

Verastem Announces Promising Phase 1 Study Results

June 2, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, RIGL, VSTM, and VNDA Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$2.23 -1.28 (-36.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.24 +0.02 (+0.67%)

As of 04:00 AM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Rigel Pharmaceuticals NASDAQ:RIGL

$19.48 +0.72 (+3.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$19.52 +0.04 (+0.21%)

As of 06/27/2025 05:08 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.78 -0.04 (-0.83%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.15 +0.37 (+7.74%)

As of 04:00 AM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Verastem NASDAQ:VSTM

$4.15 -0.01 (-0.24%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.33 +0.18 (+4.34%)

As of 04:00 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time